$ELDN
Eledon Pharmaceuticals, Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023021372 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.153M $2.997M $3.224M
YoY Change -10.93% -7.04% -3.76%
% of Gross Profit
Research & Development $7.201M $8.113M $6.635M
YoY Change 25.39% 22.28% 17.37%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $10.35M $11.11M $9.859M
YoY Change 11.54% 12.69% 9.48%
Operating Profit -$10.35M -$11.11M -$9.859M
YoY Change 11.54% 12.69% 9.48%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $775.0K $338.0K -$5.000K
YoY Change 2052.78% -6860.0% -200.0%
Pretax Income -$9.579M -$10.77M -$9.864M
YoY Change 3.59% 9.21% 9.6%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$9.579M -$10.77M -$9.864M
YoY Change 3.59% 9.21% 16.06%
Net Earnings / Revenue
Basic Earnings Per Share -$0.40 -$0.75 -$0.69
Diluted Earnings Per Share -$0.40 -$0.75 -$688.3K
COMMON SHARES
Basic Shares Outstanding 22.51M 13.78M 14.33M
Diluted Shares Outstanding 24.01M 14.29M 14.33M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $71.38M $46.49M $76.68M
YoY Change 1.3% -39.38% -29.4%
Cash & Equivalents $40.95M $46.50M $76.68M
Short-Term Investments $30.43M
Other Short-Term Assets $238.0K $47.00K $17.00K
YoY Change 643.75% 176.47% -34.62%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $73.62M $48.90M $79.33M
YoY Change 1.15% -38.35% -28.04%
LONG-TERM ASSETS
Property, Plant & Equipment $553.0K $647.0K $675.0K
YoY Change -4.82% -4.15% 575.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $224.0K $369.0K $344.0K
YoY Change -26.07% 7.27% 14.67%
Total Long-Term Assets $33.16M $33.40M $82.05M
YoY Change -59.52% -59.29% 0.73%
TOTAL ASSETS
Total Short-Term Assets $73.62M $48.90M $79.33M
Total Long-Term Assets $33.16M $33.40M $82.05M
Total Assets $106.8M $82.31M $161.4M
YoY Change -30.98% -49.0% -15.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.197M $2.852M $1.026M
YoY Change 66.69% 177.97% -31.6%
Accrued Expenses $2.703M $2.626M $1.932M
YoY Change 38.05% 35.92% -28.44%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.900M $5.478M $2.958M
YoY Change 49.57% 85.19% -29.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $184.0K $284.0K $350.0K
YoY Change -38.46% -18.86%
Total Long-Term Liabilities $184.0K $284.0K $350.0K
YoY Change -38.46% -18.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.900M $5.478M $2.958M
Total Long-Term Liabilities $184.0K $284.0K $350.0K
Total Liabilities $6.836M $7.514M $5.060M
YoY Change 28.33% 48.5% -35.22%
SHAREHOLDERS EQUITY
Retained Earnings -$223.2M -$213.6M -$124.8M
YoY Change 66.57% 71.15% 40.4%
Common Stock $323.2M $288.4M
YoY Change 14.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $99.95M $74.79M $156.3M
YoY Change
Total Liabilities & Shareholders Equity $106.8M $82.31M $161.4M
YoY Change -30.98% -49.0% -15.81%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$9.579M -$10.77M -$9.864M
YoY Change 3.59% 9.21% 16.06%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$8.221M -$9.924M -$8.156M
YoY Change 32.23% 21.68% 57.88%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$30.33M
YoY Change
Cash From Investing Activities -$30.33M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 33.02M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -8.221M -9.924M -8.156M
Cash From Investing Activities -30.33M
Cash From Financing Activities 33.02M 0.000
Net Change In Cash -5.538M -9.924M -8.156M
YoY Change -10.92% 21.68% 45.23%
FREE CASH FLOW
Cash From Operating Activities -$8.221M -$9.924M -$8.156M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001404281
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-36620
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
ELEDON PHARMACEUTICALS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-1000967
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
19900 MacArthur Blvd
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 550
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Irvine
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92612
CY2023Q1 dei City Area Code
CityAreaCode
(949)
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
238-8090
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2023Q1 dei Trading Symbol
TradingSymbol
ELDN
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22506956
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46485000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56409000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2419000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3109000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
48904000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
59518000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
647000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
739000
CY2023Q1 eldn In Process Research And Development
InProcessResearchAndDevelopment
32386000
CY2022Q4 eldn In Process Research And Development
InProcessResearchAndDevelopment
32386000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
369000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
150000
CY2023Q1 us-gaap Assets
Assets
82306000
CY2022Q4 us-gaap Assets
Assets
92793000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2852000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2200000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
384000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
363000
CY2023Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2242000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3912000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5478000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6475000
CY2023Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1752000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1752000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
284000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
383000
CY2023Q1 us-gaap Liabilities
Liabilities
7514000
CY2022Q4 us-gaap Liabilities
Liabilities
8610000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13776788
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13776788
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13776788
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13776788
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
14000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
14000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
288415000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
287034000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-213637000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-202865000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
74792000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
84183000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
82306000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
92793000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8113000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6635000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2997000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3224000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
11110000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
9859000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11110000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9859000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
338000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10772000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9864000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14285905
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14285905
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14330693
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14330693
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
84183000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1381000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10772000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
74792000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
163995000
CY2022Q1 eldn Cancellation Of Common Stock In Exchange For Preferred Stock Value
CancellationOfCommonStockInExchangeForPreferredStockValue
1000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2186000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9864000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
156318000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10772000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9864000
CY2023Q1 eldn Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
92000
CY2022Q1 eldn Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
93000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1381000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2186000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-471000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-921000
CY2023Q1 eldn Accounts Payable Accrued Expenses And Other Liabilities
AccountsPayableAccruedExpensesAndOtherLiabilities
-1018000
CY2022Q1 eldn Accounts Payable Accrued Expenses And Other Liabilities
AccountsPayableAccruedExpensesAndOtherLiabilities
-1401000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-78000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-91000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9924000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8156000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9924000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8156000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56409000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84833000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46485000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76677000
CY2022Q1 eldn Common Stock Exchanged For X One Non Voting Convertible Preferred Stock
CommonStockExchangedForXOneNonVotingConvertiblePreferredStock
1000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10800000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-213600000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46500000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to stock-based compensation, accruals for liabilities, impairment of long-lived assets, and other matters that affect the consolidated financial statements and related disclosures. Actual results could differ materially from those estimates under different assumptions or conditions and the differences may be material to the consolidated financial statements.</span></p>
CY2023Q1 eldn Cash Cash Equivalents And Restricted Cash Maturity Period
CashCashEquivalentsAndRestrictedCashMaturityPeriod
three months or less
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
9400000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
9300000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
50000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
112000
CY2023Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2242000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3912000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2023Q1 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
0
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10772000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9864000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14285905
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14285905
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14330693
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14330693
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10238198
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8316473
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
534000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
823000
CY2023Q1 eldn Prepaid Clinical Expense
PrepaidClinicalExpense
1580000
CY2022Q4 eldn Prepaid Clinical Expense
PrepaidClinicalExpense
2115000
CY2023Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
258000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
143000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
47000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
28000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2419000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3109000
CY2023Q1 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
845000
CY2022Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1909000
CY2023Q1 eldn Accrued Clinical Current
AccruedClinicalCurrent
1141000
CY2022Q4 eldn Accrued Clinical Current
AccruedClinicalCurrent
1826000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
206000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
65000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
102000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
83000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
97000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M12D
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y1M28D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0249
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0300
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
295000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
388000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
683000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
15000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
668000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
384000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
284000
CY2023Q1 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2023Q1 eldn Contingent Liability
ContingentLiability
0
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1381000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2186000

Files In Submission

Name View Source Status
0000950170-23-021372-index-headers.html Edgar Link pending
0000950170-23-021372-index.html Edgar Link pending
0000950170-23-021372.txt Edgar Link pending
0000950170-23-021372-xbrl.zip Edgar Link pending
eldn-20230331.htm Edgar Link pending
eldn-20230331.xsd Edgar Link pending
eldn-20230331_cal.xml Edgar Link unprocessable
eldn-20230331_def.xml Edgar Link unprocessable
eldn-20230331_lab.xml Edgar Link unprocessable
eldn-20230331_htm.xml Edgar Link completed
eldn-ex31_1.htm Edgar Link pending
eldn-ex31_2.htm Edgar Link pending
eldn-ex32_1.htm Edgar Link pending
eldn-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
eldn-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable